Wockhardt growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue+12.0%+8.4%
EBITDA+66.0%+86.2%
Total Assets+5.9%+3.9%
Total Equity+13.4%+13.0%
Free Cash Flow—+31.8%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

WOCKPHARMA₹1,922.90

Wockhardt Ltd.

· Pharma & Health
₹ CrorePeersBIOCONSYNGENEASTERDMGLANDPPLPHARMACOHANCELALPATHLABNATCOPHARMMcap ₹31,151 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue+12.0+8.4
EBITDA+66.0+86.2
Total Assets+5.9+3.9
Total Equity+13.4+13.0
Free Cash Flow—+31.8
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.